Background and aims: Statins have been suggested to exert anticancer properties by modulating angiogenesis, fibrosis, inflammation, and the tumor microenvironment, generating interest in their clinical use for chronic liver diseases (CLD) and hepatocellular carcinoma (HCC) chemoprevention. However, the effects of statin therapy in patients treated with immune checkpoint inhibitors for CLDassociated HCC remain unknown. This study primarily aimed to assess the potential effect of statins on overall survival (OS) and progression-free survival (PFS) in patients with advanced HCC treated with atezolizumab and bevacizumab (A+B). Method: The ARTE dataset, a retro-prospectively maintained database, includes 305 consecutive patients with unresectable HCC treated with A+B, enrolled from 12 tertiary care centers in Italy. From the original cohort, a 1:1 propensity score matching was performed to balance potential confounding factors between 63 patients on statin therapy and those who were not. The primary outcomes were OS and PFS, while secondary outcomes included all-cause mortality, liver-related death, treatment interruption, and incidence of liver decompensation events.Results: Among the matched population of 126 patients, 75% had liver cirrhosis, with metabolic disfunction -associated steatotic liver disease (MASLD) being the most common etiology. Ninety-seven patients (32%) had diabetes. No significant differences were found between statin users and non-users for OS, PFS, or liver-related death. Additionally, the log-rank test revealed no significant difference between the groups in terms of treatment interruption due to liver decompensation events (p=0.28). Conclusion: Statin use did not show any impact on OS, PFS, or reduction in mortality or treatment interruption due to liver-related decompensation events in patients with advanced HCC treated with A+B.
PO6-11 Statins in patients with advanced HCC treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from ARTE an Italian prospective multicentric dataset
Stella, LeonardoData Curation
;
2025-01-01
Abstract
Background and aims: Statins have been suggested to exert anticancer properties by modulating angiogenesis, fibrosis, inflammation, and the tumor microenvironment, generating interest in their clinical use for chronic liver diseases (CLD) and hepatocellular carcinoma (HCC) chemoprevention. However, the effects of statin therapy in patients treated with immune checkpoint inhibitors for CLDassociated HCC remain unknown. This study primarily aimed to assess the potential effect of statins on overall survival (OS) and progression-free survival (PFS) in patients with advanced HCC treated with atezolizumab and bevacizumab (A+B). Method: The ARTE dataset, a retro-prospectively maintained database, includes 305 consecutive patients with unresectable HCC treated with A+B, enrolled from 12 tertiary care centers in Italy. From the original cohort, a 1:1 propensity score matching was performed to balance potential confounding factors between 63 patients on statin therapy and those who were not. The primary outcomes were OS and PFS, while secondary outcomes included all-cause mortality, liver-related death, treatment interruption, and incidence of liver decompensation events.Results: Among the matched population of 126 patients, 75% had liver cirrhosis, with metabolic disfunction -associated steatotic liver disease (MASLD) being the most common etiology. Ninety-seven patients (32%) had diabetes. No significant differences were found between statin users and non-users for OS, PFS, or liver-related death. Additionally, the log-rank test revealed no significant difference between the groups in terms of treatment interruption due to liver decompensation events (p=0.28). Conclusion: Statin use did not show any impact on OS, PFS, or reduction in mortality or treatment interruption due to liver-related decompensation events in patients with advanced HCC treated with A+B.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
